MDxHealth SA has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences (NASDAQ:EXAS) as well as the latter's urology sales and marketing team. Under the deal, MDxHealth (MDXH) paid $25M in cash, plus another $5M worth of American Depository Shares. Exact Sciences (EXAS) can also receive up to an additional $70M based on revenue milestones in fiscal years 2023 through 2025. MDxHealth is financing the acquisition through a $35M loan with an affiliate of Innovatus Capital Partners. An additional $35 million can be drawn from Innovatus through a $20M term B loan and a $15 million term C loan in, respectively, 2024 and 2025. After Tuesday's closing bell, Exact Sciences' (EXAS) Q2 2022 results beat on the top and bottom lines though the company lowered its full-year guidance.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!